Please assess the completion status of the following clinical trial:

Trial Title: A Trial Of SU14813 In Patients With Advanced Solid Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a histologically proven advanced solid malignancy for which no recognized therapy was available or for which standard therapy had failed~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~* Serum albumin ≥3.0 g/dL and adequate haemopoietic, renal and liver function~Exclusion Criteria:~* Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy or an investigational agent within 4 weeks before the start of study treatment~* Subjects had to have recovered from all prior treatment toxicities, except alopecia, and from any major surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SU014813 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).